For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Eli Lilly and (LLY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for LLY's full-year earnings has moved 2.06% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that LLY has returned about 35.99% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.51% on a year-to-date basis. As we can see, Eli Lilly and is performing better than its sector in the calendar year.
To break things down more, LLY belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #66 in the Zacks Industry Rank. This group has gained an average of 12.06% so far this year, so LLY is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Eli Lilly and (LLY - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of LLY and the rest of the Medical group's stocks.
Eli Lilly and is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for LLY's full-year earnings has moved 2.06% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that LLY has returned about 35.99% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.51% on a year-to-date basis. As we can see, Eli Lilly and is performing better than its sector in the calendar year.
To break things down more, LLY belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #66 in the Zacks Industry Rank. This group has gained an average of 12.06% so far this year, so LLY is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on LLY - FREE